Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
Sponsor: Peking Union Medical College Hospital
Summary
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
3000
Start Date
2024-04-19
Completion Date
2027-04-19
Last Updated
2026-01-06
Healthy Volunteers
No
Conditions
Interventions
Irinotecan liposome II combination therapy regimen
Irinotecan liposome II combination therapy regimen
Locations (10)
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Peking Unicersity First Hospital
Beijing, China
Henan Provincial People's Hospital
Henan, China
Ningbo Medical Center Lihuili Hospital
Ningbo, China
Fudan University Shanghai Cancer Center
Shanghai, China
Renji，Hospital
Shanghai, China
Wuhan Union Hospital of China
Wuhan, China